Direct Oral Anticoagulants Have Distinct Bleeding Profiles

Share this content:
Direct Oral Anticoagulants Have Distinct Bleeding Profiles
Direct Oral Anticoagulants Have Distinct Bleeding Profiles

(HealthDay News) -- Direct oral anticoagulants (DOACs) have distinct bleeding profiles and require individualized management approaches, according to a state-of-the-art review published in the December issue of JACC: Cardiovascular Interventions.

Jerrold H. Levy, M.D., from Duke University in Durham, N.C., and colleagues reviewed the safety of DOACs, which are approved for multiple thromboembolic disorders.

The researchers note that DOACs provide advantages over existing agents. In randomized phase III studies, DOACs were found to have a similar risk of clinically relevant bleeding compared with standard anticoagulants, with declines in major bleeding in some cases, especially for patients with atrial fibrillation, for whom the rate of intracranial hemorrhage was approximately halved with DOACs versus warfarin. However, the risk of gastrointestinal bleeding may be increased with DOACs. When assessing the risk of bleeding, specific patient characteristics, such as renal impairment, comedications, and aspects of each drug should be considered. Routine coagulation monitoring of DOACs may be useful in some situations, although it is not required. A sensitive and calibrated prothrombin time may be useful for detecting clinically relevant factor Xa inhibitor concentrations; drug levels can be measured quantitatively with specific anti-factor Xa assays.

"Further study and increasing use of apixaban, rivaroxaban, dabigatran, and edoxaban in real-world practice will help to familiarize physicians with best practice in this area," the authors write. "Development of specific measurement techniques and reversal agents will also provide further tools for the management of bleeding."

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

NIH Panel Will No Longer Review Gene Therapy Experiments

NIH Panel Will No Longer Review Gene Therapy ...

FDA will now assess gene therapy experiments and products as it does with other treatments, drugs

Doctors Remove Contact Lens Embedded in Eyelid for Years

Doctors Remove Contact Lens Embedded in Eyelid for ...

Lens was encapsulated within the upper eyelid soft tissue since childhood eye trauma

CDC: Brucellosis in Dogs Remains a Public Health Risk

CDC: Brucellosis in Dogs Remains a Public Health ...

Infection is under-recognized, may remain a threat without stronger intervention measures

is free, fast, and customized just for you!




Already a member?

Sign In Now »